AstraZeneca-Daiichi Sankyo Enhertu gets USFDA accelerated nod for metastatic HER2-positive solid tumours Ruchika Sharma7 April 2024 11:30 AM ISTCambridge: AstraZeneca and Daiichi Sankyo's Enhertu (trastuzumab deruxtecan) has been approved in the US for the treatment of adult patients...
AstraZeneca, Daiichi Sankyo Datopotamab deruxtecan application accepted in US for pretreated metastatic HR-positive, HER2-negative breast cancer Ruchika Sharma3 April 2024 12:30 PM ISTAstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US for the...
USFDA nod to Voydeya as add on therapy to ravulizumab or eculizumab for extravascular haemolysis in adults with rare disease PNH: AstraZeneca Ruchika Sharma1 April 2024 3:18 PM ISTCambridge: AstraZeneca has announced that Voydeya (danicopan) has been approved in the US as add-on therapy to ravulizumab or eculizumab for the...
AstraZeneca Truqap plus Faslodex gets nod in Japan for advanced HR-positive breast cancer Ruchika Sharma31 March 2024 2:30 PM ISTCambridge: AstraZeneca's Truqap (capivasertib) in combination with Faslodex (fulvestrant) has been approved in Japan for the treatment of adult...
AstraZeneca-Sanofi Beyfortus approved in Japan for prevention of RSV disease in infants Ruchika Sharma31 March 2024 12:30 PM ISTCambridge: AstraZeneca and Sanofi's Beyfortus (nirsevimab), a long-acting monoclonal antibody, has been approved in Japan for the prophylaxis of...
AstraZeneca to acquire Fusion Pharma to accelerate development of next-generation radioconjugates to treat cancer Susmita Roy19 March 2024 4:11 PM ISTCambridge: AstraZeneca has entered into a definitive agreement to acquire Fusion Pharmaceuticals Inc., a clinical-stage biopharmaceutical company...
AstraZeneca to acquire Amolyt Pharma for USD 1.05 billion Susmita Roy15 March 2024 2:17 PM ISTCambridge: AstraZeneca has announced that it has entered into a definitive agreement to acquire Amolyt Pharma, a clinical-stage biotechnology...
EMA validates marketing authorisation applications for AstraZeneca, Daiichi Sankyo datopotamab deruxtecan in lung, breast cancer Ruchika Sharma6 March 2024 3:25 PM ISTCambridge: The European Medicines Agency (EMA) has validated two marketing authorisation applications (MAAs) for AstraZeneca and Daiichi Sankyo’s...
AstraZeneca blood disorder drug recommended for EU nod Ruchika Sharma27 Feb 2024 11:29 AM ISTCambridge: AstraZeneca has announced that Voydeya (danicopan) has been recommended for marketing authorisation in the European Union (EU) as an...
AstraZeneca completes acquisition of Gracell Biotechnologies Ruchika Sharma23 Feb 2024 12:30 PM ISTGracell will operate as a wholly owned subsidiary of AstraZeneca, with operations in China and the US.
AstraZeneca concludes acquisition of Icosavax Ruchika Sharma20 Feb 2024 12:30 PM ISTCambridge: AstraZeneca has announced the successful completion of the acquisition of Icosavax, Inc., a US-based clinical-stage biopharmaceutical...
AstraZeneca-Daiichi Sankyo application for Datopotamab deruxtecan accepted in US for patients with previously treated advanced nonsquamous non-small cell lung cancer Ruchika Sharma19 Feb 2024 4:30 PM ISTCambridge: AstraZeneca and Daiichi Sankyo's Biologics License Application (BLA) for datopotamab deruxtecan (Dato-DXd) has been accepted in the US...
